Shorter hormone therapy for low-risk postmenopausal breast cancer
Part of Cancer, Skin clinical trials.
This Phase 2 trial studies whether women with very low-risk, hormone-receptor positive breast cancer can safely take hormone therapy for a shorter time. It may help reduce side effects if shorter treatment works as well as the longer standard plan.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are postmenopausal (for example, age 60+ or no periods for 12+ months after age 50).
- Your breast cancer tests show estrogen/progesterone receptors strongly positive (50% or more).
- Your cancer is HER2 negative, and your tumor has been fully removed with axillary (armpit) surgery done.
- Your cancer is early and low stage (no spread to distant sites; lymph nodes negative; small tumor size; low grade).
- You started or can start an aromatase-inhibitor hormone pill (letrozole, anastrozole, or exemestane) within the allowed time window.
- Your tumor’s “ultralow risk” score from MammaPrint and BluePrint is below the cutoff (needed to qualify).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing how well a short course of hormone-blocking pills (endocrine therapy) works before surgery in women with early-stage hormone receptor-positive HER2-negative breast cancer. The goal is to understand what makes some cancers resistant to these treatments.
This study looks at whether taking hormone-blocking pills for longer than 5 years can help lower the risk of breast cancer returning. It is for people who had lymph node involvement and have already completed their initial 5-year treatment without the cancer coming back.
This Phase 3 trial checks whether adding chemotherapy after standard hormone-blocking treatment works better for some premenopausal women with early-stage, ER-positive, HER2-negative breast cancer. It targets patients with limited lymph node spread and a lower-to-intermediate tumor “recurrence” risk score.
This study looks at young women with early-stage breast cancer who are premenopausal (still having periods) and have a low-to-intermediate Oncotype score, to see how well hormone therapy works. It aims to understand if current treatment decisions are appropriate.
This trial tests a new oral drug (HRS-8080) against standard hormone therapy for women with intermediate- or high-risk early breast cancer who have already completed 2 to 5 years of hormone treatment. It aims to see if the new drug can reduce the risk of cancer coming back.
This Phase 2 trial tests a shorter, focused radiation treatment after breast surgery, either alone or with an extra targeted boost. It’s for people with low-risk breast cancer and no spread to distant organs, aiming to keep results while reducing treatment time and side effects.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.